Q4 2018 Allogene Therapeutics Inc Earnings Call Transcript
Good morning, ladies and gentlemen. Thank you for standby, and welcome to Allogene Therapeutics' Fourth Quarter 2018 Conference Call. (Operator Instructions) Please be aware that today's conference call is being recorded.
I would now like to turn the conference over to Christine Cassiano, Chief Communications Officer. Ms. Cassiano, please go ahead.
Thank you, operator, and good morning. Before market opened today, Allogene issued a press release to provide the corporate update and financial results for the fourth quarter and full year ended December 31, 2018. This press release is available on our website at www.allogene.com. We will also be discussing our ALLO-501 Phase I clinical trial protocol and have posted on our website a slide, which provides an overview of the trial. This can be found in the Investors section under News & Events.
We remind listeners that today's call is being webcast on
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |